Question Title

1. A liver transplant recipient being treated for CMV infection asks whether it can affect his transplant beyond making him feel unwell. In addition to tissue-invasive disease, CMV infection after transplant is associated with which of the following? (Required.)

Question Title

2. Which of the following scenarios should raise the greatest concern for progression toward refractory/resistant CMV? (Required.)

Question Title

3. A clinician is reviewing treatment options for refractory/resistant CMV after renal transplant. Which statement best reflects current evidence and practical treatment differentiation? (Required.)

Question Title

4. A heart transplant recipient with CMV DNAemia has completed 5 weeks of appropriately dosed IV ganciclovir. Her viral load initially declined, then plateaued, and this week has risen by 0.7 log10 IU/mL. She remains on full-dose therapy with adequate drug exposure. According to current consensus guidelines, what is the best next step? (Required.)

Question Title

5. What is your highest attained credential? (Required.)

Question Title

6. What is your specialty? (Required.)

Question Title

7. Which of the following describes your primary practice setting? (Required.)

Question Title

8. How many years have you been in practice? (Please use numbers only) (Required.)

Question Title

9. How many solid organ transplant or hematopoietic cell transplant recipients with CMV infection or disease do you see/manage per MONTH? (Please use numbers only) (Required.)

Question Title

10. Please let us know how this activity will help you with patient care. (Required.)

Question Title

11. Please rate how well the activity met the identified objective:

  Strongly Agree Agree Neutral Disagree Strongly Disagree
Recognize the full range of outcomes associated with post-transplant CMV infection, including the burden of refractory/resistant disease and its impact on the patient experience.
Proactively identify patients who are at risk for post-transplant CMV infection and for progression to refractory/resistant CMV in routine clinical practice.
Differentiate approved therapies for CMV infection in the post-transplant setting using contemporary real-world evidence to optimize outcomes.
Develop strategies to treat CMV infection, including refractory/resistant infection, based on the latest consensus guidelines.

Question Title

12. Please rate the effectiveness of the presenting faculty: (Required.)

  Strongly Agree Agree Neutral Disagree Strongly Disagree
The faculty was effective in presenting the material
The faculty was knowledgeable about the subject matter

Question Title

13. Please rate the effectiveness of the CME/CE content: (Required.)

  Strongly Agree Agree Neutral Disagree Strongly Disagree
The content addressed the learning objectives (purpose)
The activity enhanced my current knowledge base
The information was relevant to my practice and my educational needs
The information will help me improve patient care
The activity provided new ideas or information I expect to use
The activity provided appropriate learning assessment activities
The activity addressed the ABMS/ACGME core competencies of patient care, professionalism, and medical knowledge

Question Title

14. Based upon your participation in this activity, do you intend to change your practice behavior? Choose only one of the following options:

Question Title

15. If you plan to change your practice behavior, what types of changes do you plan to implement? Check all that apply:

Question Title

16. How confident are you that you will be able to make your intended changes?

Question Title

17. In what time frame do you anticipate making these intended changes?

Question Title

18. Which of the following parameters do you anticipate will be the primary barrier to implementing these changes? Please choose only one of the following options and provide any additional details in the box below:

Question Title

19. Was the content of this activity fair, balanced, objective, and free of bias?

Question Title

20. How confident were/are you in identifying patients at risk for post-transplant CMV infection and for progression to refractory/resistant disease?

  Very Confident Confident Somewhat Confident Unsure Not Very Confident
Before this activity?
After this activity

Question Title

21. How confident were/are you in selecting guideline-recommended treatment for refractory/resistant CMV infection?

  Very Confident Confident Somewhat Confident Unsure Not Very Confident
Before this activity?
After this activity

Question Title

22. How confident were/are you in differentiating the approved antiviral therapies for CMV infection based on their efficacy, safety, and tolerability, and real-world data?

  Very Confident Confident Somewhat Confident Unsure Not Very Confident
Before this activity?
After this activity

Question Title

23. How confident were/are you in counseling transplant recipients about CMV infection and the burden of its treatment?

  Very Confident Confident Somewhat Confident Unsure Not Very Confident
Before this activity?
After this activity

Question Title

24. Use of comics in adult education is well established. Specifically, they have been shown to foster retention and engagement with science curricula, enhance health care provider–patient communication, and help health care providers gain insights into patients’ experiences. Recently, the American Medical Association included comic creation among their certified CME activities.

With this in mind, what did you think of the use of comic illustrations in the case studies and why? Please be as specific as possible.

Question Title

25. How did hearing Everardo's experience of living with resistant CMV help you think about how you support your transplant patients? Please be as specific as possible.

Question Title

26. Complete to receive your credit

Thank you for participating! Please click "Done" to submit your answers. You will receive your certificate via email within 3 weeks.

T